Search results
Results from the WOW.Com Content Network
Theophylline is excreted unchanged in the urine (up to 10%). Clearance of the drug is increased in children (age 1 to 12), teenagers (12 to 16), adult smokers, elderly smokers, as well as in cystic fibrosis, and hyperthyroidism. Clearance of the drug is decreased in these conditions: elderly, acute congestive heart failure, cirrhosis ...
Xanthine (/ ˈ z æ n θ iː n / or / ˈ z æ n θ aɪ n /, from Ancient Greek ξανθός xanthós ' yellow ' for its yellowish-white appearance; archaically xanthic acid; systematic name 3,7-dihydropurine-2,6-dione) is a purine base found in most human body tissues and fluids, as well as in other organisms. [2]
Because one of the active ingredients in Tedral is theophylline, Tedral is contraindicated if the patient has: [3] [6] Hypersensitivity to xanthine derivatives; Coronary artery disease (cardiac stimulating effects of Theophylline may prove harmful) Peptic ulcer; Concomitant use with ephedrine in children.
Paraxanthine, also known as 1,7-dimethylxanthine, is an isomer of theophylline and theobromine, two well-known stimulants found in coffee, tea, and chocolate mainly in the form of caffeine. It is a member of the xanthine family of alkaloids , which includes theophylline, theobromine and caffeine .
Methylxanthines, including theophylline, aminophylline and dyphylline, are a class of drugs that can achieve bronchodilation and reduce bronchospasm for symptomatic control of asthma. [ 7 ] Methylxanthines act as a competitive inhibitor of phosphodiesterase , inhibiting phosphodiesterase degradation action of cyclic 3′,5′-adenosine ...
8-Phenyltheophylline (8-phenyl-1,3-dimethylxanthine, 8-PT) is a drug derived from the xanthine family which acts as a potent and selective antagonist for the adenosine receptors A 1 and A 2A, but unlike other xanthine derivatives has virtually no activity as a phosphodiesterase inhibitor.
In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects. [5] In February 2014, the US FDA granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals, in May 2013. [6] [7] [8]
Theophylline has also been marketed in combination with other ephedrine-like sympathomimetics like racephedrine and pseudoephedrine and with other barbiturates such as amobarbital and butabarbital, among other drugs. [15] A combination of theophylline, ephedrine, and hydroxyzine has been marketed under the brand name Marax among others as well.